非小细胞肺癌环氧化酶-2的增强表达及其临床意义

目的 探讨环氧化酶-2(COX-2)在非小细胞肺癌组织中的表达水平与其临床特征和预后的关系。方法 收集外科切除的79例非小细胞肺癌的组织标本石蜡切片,应用抗人COX-2抗体进行免疫组织化学染色,用COX-2阳性表达血管内皮细胞作阳性对照。结果 肺腺癌和鳞癌COX-2阳性表达率分别为85％(28／33)和57％(26／46)(P=0．013),COX-2的表达与腺癌的分化程度(P=0．007)、肿瘤的大小(P=0．011)和TNM分期有密切关系(P=0．021),与鳞癌分化程度无明显关系(P=0．550)。COX-2阳性组患者5年生存率27．1％,中位生存期53个月;COX之阴性组患者5年生存率52．0％,中位生存期61个月,2组差异有显著性意义(P=0．029)。结论 COX-2的增强表达与非小细胞肺癌的浸润性发展有密切关系,是非小细胞肺癌患者预后不良的风险因素之一。

Overexpression of COX-2 and its clinical significance in non-small cell lung cancer

ObjectiveTo study the relations among COX-2 expression in non-small cell lung cancer(NSCLC), its clinical characteristics and brognosis.MethodsImmunostaining was performed with COX-2 antibody to the surgically resected tissue samples from 79 patients with NSCLC. Vessel epithelium cell COX-2 expression was taken as positive control.ResultsThe positive rate of adenocarcinoma and squamous cell carcinoma was 85% and 57%, respectively( P =0.013). COX-2 expression was associated with the extent of adenocarcinoma differentiation, tumor size, and TNM period, but not with the extent of squamous cell carcinoma differentiation. In the COX-2 positive group, the 5-year survival rate and a median survival time were 27.1% and 53 months; however in the negative group they were 52.0% and 61 months ( P =0.029).ConclusionInvasive development of NSCLC is related to inceased expression of COX-2. COX-2 overexpression may be one of the risky factors for the prognosis of NSCLC.